Brentwood, TN, United States
Brentwood, TN, United States

Time filter

Source Type

Patent
DiaTech Oncology | Date: 2015-04-23

The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.


Methods of isolating and purifying hematologic or non-hematologic tumor cells useful in a variety of assays and procedures, including tumor drug efficacy screening such as Microculture Kinetic assays, are disclosed herein. Further, Microculture Kinetic assays and methods suitable for comparing the relative efficacy of generic versus proprietary anti-cancer drugs are also disclosed.


Patent
DiaTech Oncology | Date: 2010-03-31

The disclosure provides a method of evaluating the ability of an anti-cancer drug candidate to induce apoptosis in a known cancer cell line by placing a single-cell suspension of a known cancer cell line in a well of a plate, adding at least one drug candidate to the well in an amount sufficient to achieve a target drug candidate concentration, measuring the optical density at selected time intervals for a selected duration of time, determining a kinetic units value from the optical density and time measurements, and correlating the kinetic units value with an ability of the anti-cancer drug candidate to induce apoptosis in the cancer cell line if the kinetic units value is positive. A similar method may be used to evaluate the ability of an anti-cancer drug candidate to induce apoptosis in a cancer type.


Trademark
DiaTech Oncology | Date: 2011-07-28

Pharmaceutical preparations for the treatment of cancer; Drug testing kits comprised of medical diagnostic reagents and assays for testing specimens; Medical diagnostic reagents and assays for testing of body specimens; Medical diagnostic reagents and assays for testing of apoptosis concentrations to determine the most effective oncological treatments. Medical services; Medical testing for diagnostic or treatment purposes in the field of oncology and testing drug effectiveness; Medical testing for diagnostic or treatment purposes; Medical diagnostic testing, monitoring and reporting services.


Trademark
DiaTech Oncology | Date: 2016-05-19

Drug testing kits comprised of medical diagnostic reagents and assays for testing specimens; medical diagnostic reagents and assays for testing of body specimens; medical diagnostic reagents and assays for testing of cytotoxic, targeted biologic and immunotherapeutic treatments to determine the most effective oncological treatments. Medical testing for diagnostic or treatment purposes in the field of oncology and testing drug effectiveness; medical testing for diagnostic or treatment purposes; medical diagnostic testing, monitoring and reporting services.


A computer system is provided for determining the relative effectiveness of anti-cancer drugs. The interface has selectable options, including an option to manage drug testing parameters, and enables user selection of desired drug testing parameters in relation to a virtual well plate associated with a physical well plate of a spectrophotometer. The computer system causes the spectrophotometer to start a drug test, wherein the physical well plate includes at least one test well containing viable cancer cells; and at least one drug candidate in a predetermined concentration; and at least one control well containing the viable cancer cells alone. The system records the optical density of the well at a predetermined wavelength at selected time intervals for a selected duration of time, and stores the optical density and time measurements in the database. An activity value is calculated from the optical density and time measurements, and a correlation is displayed between the activity value and the drug candidates ability to induce apoptosis in the cancer cells.


Trademark
DiaTech Oncology | Date: 2011-07-19

Drug testing kits comprised of medical diagnostic reagents and assays for testing specimens; Medical diagnostic reagents and assays for testing of body specimens; Medical diagnostic reagents and assays for testing of apoptosis concentrations to determine the most effective oncological treatments. Medical testing for diagnostic or treatment purposes in the field of oncology and testing drug effectiveness; Medical testing for diagnostic or treatment purposes; Medical diagnostic testing, monitoring and reporting services.


DiaTech Oncology, provider of CorrectChemo®, the industry leading functional drug response profiling test to help oncologists provide personalized cancer treatment, has gained accreditation from the College of American Pathologists (CAP) for its laboratories in the U.S. and Canada. “Receiving the CAP certification is equivalent to the ‘Good Housekeeping’ seal of approval,” says Robert E. Henry, president and chief executive officer for DiaTech. “It’s a rigorous inspection that confirms our labs adhere to the strictest quality standards for conducting the CorrectChemo test.” The CorrectChemo assay, developed by DiaTech, is the only diagnostic test available that identifies, within 72 hours, how effective a variety of chemotherapy drugs may be in killing cancer cells in an individual patient sample. This patient-specific cancer testing provides oncologists with a unique data set to develop a treatment plan tailored to each patient’s individual chemotherapy needs. Clinically published studies have shown that utilization of the test results in improved survival rates, including a 28 percent increase for breast cancer patients and a 68 percent increase for ovarian cancer patients. DiaTech’s labs in Franklin, Tenn., and Montreal, Canada already have CLIA (Clinical Laboratory Improvement Amendments 1988) regulatory approval, which is required by CMS Medicare. The CAP certification is a step beyond CLIA and requires a lengthy application process and onsite laboratory inspections. DiaTech’s CAP listing for both of its labs can be found here. Based in Franklin, Tenn., Diatech Oncology is a privately held life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. Now called CorrectChemo, the test evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective in inducing cancer cell death. It is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. DiaTech has CLIA and CAP certified laboratories in Franklin, Tenn. and Montreal, Canada.


News Article | June 30, 2015
Site: www.prweb.com

DiaTech Oncology, provider of CorrectChemo®, the drug response profiling test to help oncologists provide personalized cancer treatment, will be available through NextGxDx’s online genetic testing marketplace, GeneSourceTM. “The CorrectChemo® assay provides the oncologist with valuable insight on how a specific patient’s cancer cells react to the drugs being considered for chemotherapy treatment,” said Robert E. Henry, president and chief executive officer for DiaTech. “The NextGxDx platform enhances our market reach, and we’re pleased to be a part of their platform.” Adding DiaTech’s CorrectChemo assay to its platform continues NextGxDx’s efforts to broaden the scope of cancer diagnostics in its GeneSource catalog with emerging cell-based assays. CorrectChemo is the only diagnostic test available that delivers, within 72 hours, a ranking of the ability of chemotherapeutic agents to kill tumor cells in an individual patient sample. This patient-specific cancer testing provides oncologists with a unique data set to develop a treatment plan tailored to each patient’s individual chemotherapy needs. Clinically published studies have shown that CorrectChemo utilization resulted in improved survival rates. DiaTech’s laboratories in Franklin, Tennessee, and Montreal, Canada are CLIA-certified, and were recently accredited through College of American Pathology. In addition, DiaTech is also a Medicare approved lab. “As a company, we seek to inform our thousands of users about innovative tests in the marketplace, and are especially pleased to add DiaTech Oncology’s CorrectChemo assay,” stated Mark Harris, PhD, MBA and chief executive officer of NextGxDx. “We believe this diagnostic test to be highly complimentary to our catalog of oncology-focused tests.” About Diatech Oncology Based in Franklin, Tenn., DiaTech Oncology is a privately held life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine a cancer treatment plan for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. Now called CorrectChemo, the test evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are effective in inducing cancer cell death. It is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. DiaTech has CLIA and CAP certified laboratories in Franklin, Tenn. and Montreal, Canada. About NextGxDx NextGxDx is a healthcare IT company dedicated to improving the genetic test ordering process for the medical community. GeneSourceTM, NextGxDx’s genetic testing database and online marketplace, offers healthcare providers the ability to access up-to-date listings of all genetic tests from CAP, CLIA and Medicare-approved laboratories, view pertinent information about each test, order tests online, and manage results electronically within the HIPAA-compliant portal. As the genetic testing resource, NextGxDx provides comprehensive, intuitive solutions that address the specific challenges faced by each segment of the industry. For more information, visit http://www.NextGxDx.com.

Loading DiaTech Oncology collaborators
Loading DiaTech Oncology collaborators